BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myasthenia Gravis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Myasthenia Gravis\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06607627-11169@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Klygefa (Gefurulimab): Phase 3 readout est. (NCT06607627)
DESCRIPTION:Klygefa (Gefurulimab)\, phase 3\, Generalized Myasthenia Gravis
 .\nStudy: PK\, PD\, Safety\, and Efficacy Study of Gefurulimab in Pediatri
 c Patients With AChR+ Generalized Myasthenia Gravis\nEstimated primary com
 pletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/gefurulimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06607627
URL:https://assetmemo.bio/drug/gefurulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06221501-7534@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Vyvgart (Efgartigimod Alfa): Phase 2 readout est. (NCT06221501)
DESCRIPTION:Vyvgart (Efgartigimod Alfa)\, phase 2\, Myasthenia Gravis.\nStu
 dy: Perioperative Efgartigimod for Thymoma and Myasthenia Gravis\nEstimate
 d primary completion: 30 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/efgartigimod-alfa#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06221501
URL:https://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799247-3307@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Descartes-08: Phase 3 readout est. (NCT06799247)
DESCRIPTION:Descartes-08\, phase 3\, Myasthenia Gravis.\nStudy: Investigati
 ng an mRNA CAR T-cell Therapy\, Known as Descartes-08\, as a Potential App
 roach to Treat Myasthenia Gravis\nEstimated primary completion: 30 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/descartes-08#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0679
 9247
URL:https://assetmemo.bio/drug/descartes-08#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456580-5453@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Telitacicept: Phase 3 readout est. (NCT06456580)
DESCRIPTION:Telitacicept\, phase 3\, Generalized Myasthenia Gravis.\nStudy:
  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravi
 s (UPSTREAM MG)\nEstimated primary completion: March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/telitacicept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456580
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517758-887@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06517758)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Generalized Myasthenia Gravis.
 \nStudy: A Phase III Study to Investigate Efficacy\, Safety and Tolerabili
 ty of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years 
 With gMG.\nEstimated primary completion: 30 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06517758
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596784-885@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07596784)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Myasthenia Gravis.\nStudy: 
 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Gen
 eralized Myasthenia Gravis (gMG)\nEstimated primary completion: 24 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759678
 4
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089121-3307@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Descartes-08: Phase 1/2 readout est. (NCT07089121)
DESCRIPTION:Descartes-08\, phase 1/2\, Myasthenia Gravis.\nStudy: Descartes
 -08 for Children\, Adolescents\, and Young Adults With Autoimmune Disorder
 s\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/descartes-08#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07089121
URL:https://assetmemo.bio/drug/descartes-08#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039916-10825@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Imeroprubart: Phase 3 readout est. (NCT07039916)
DESCRIPTION:Imeroprubart\, phase 3\, Myasthenia Gravis.\nStudy: Study to As
 sess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Sev
 ere Generalized Myasthenia Gravis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070399
 16
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673744-6993@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07673744)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Myasthenia Gravis.\nStudy: A 
 Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Follo
 wing Induction With Efgartigimod Administration in Participants With Myast
 henia Gravis (MG)\nEstimated primary completion: 1 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07673744
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07596901-10864@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:aritinercept: Phase 1/2 readout est. (NCT07596901)
DESCRIPTION:aritinercept\, phase 1/2\, Generalized Myasthenia Gravis.\nStud
 y: Study of Aritinercept in Patients With Generalized Myasthenia Gravis\nE
 stimated primary completion: 2 March 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/aritinercept#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07596901
URL:https://assetmemo.bio/drug/aritinercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501702-10841@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:Povetacicept: Phase 2 readout est. (NCT07501702)
DESCRIPTION:Povetacicept\, phase 2\, Myasthenia Gravis.\nStudy: A Phase 2 S
 tudy to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
 \nEstimated primary completion: 2 March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07501702
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987539-5632@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Inebilizumab: Phase 2 readout est. (NCT06987539)
DESCRIPTION:Inebilizumab\, phase 2\, Generalized Myasthenia Gravis.\nStudy:
  A Study to Evaluate the Pharmacokinetics\, Pharmacodynamics\, Safety and 
 Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravi
 s (gMG)\nEstimated primary completion: 13 March 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/inebilizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06987539
URL:https://assetmemo.bio/drug/inebilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
